|
CNBC'S MOST SHARED
- Investing in Tech Now
- Warren Buffett Tells CNBC Consumer Sales Remain "Very, Very Soft"
- Software Giants Rush to Cash In on Carbon Counting
- Preparing for Retirement
- What You'll See On My NASCAR Documentary Tonight
- Warren Buffett's Complete Sun Valley CNBC Interview - Transcript and Video
- Microsoft Plays a Game of Bing Pong
- How exactly does Twitter plan on making money?
- Playing by Different Rules
- Nikkei on Track to Break 6-Day Losing Streak
- GM CEO Vows Leaner and Better Company To Emerge
- GM CFO Young: No Positive Cash Flow Until 2009
- Geithner Seeks Clampdown on Derivatives Dealers
- Consumers' Mood Sours in Early July
- Less Demand for Fed's Emergency Backstops
- Claims Total Over 15,400 in Fraud by Madoff
- JPMorgan Asks Treasury to Auction Warrants
- UBS Can't Comply with US Request: Internal Memo
- Cisco Cutting up to 2,000 Jobs, Analyst Says
- Schork Oil Outlook: It’s Now or Never for the Bulls
- Social Networking's 'Naked' Truth
- Farrell: Let's Enjoy the Numbers for a Moment
- Call Of Shame - Vote Now
- Schmidt on Social Media, Ads and Hulu
- 15 Stocks to Consider
- Maximum Bob Goes Full Throttle For GM
- Najarian: Options Get Bullish on Cisco
- Sun Valley on Social Media
Text Size 
A new report in the Journal of the American Medical Association is highly critical of drugmaker Merck and its handling of the painkiller Vioxx.
The JAMA article says Merck [MRK
Loading...
()
] misrepresented apparent Vioxx-related deaths in studies to see if the drug worked on Alzheimer's Disease.
A review of the clinical trials, which came to light during the Vioxx litigation, shows a three-fold increase in the risk of death among the patients who got Vioxx, according to the peer-reviewed medical journal.
But in a press release, Merck says that after careful analysis there was no suggestion the deaths were caused by the drug and that the JAMA report's conclusions are "false, misleading, or lack context".
Merck voluntarily pulled Vioxx off the market in 2004 because of an increased heart risk. The company has since settled most of the resulting lawsuits for nearly $5 billion.
One of the two authors of the JAMA article was a paid expert witness for Vioxx plaintiffs.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes